- Home
- BYRN vs RLMD Comparison
BYRN vs RLMD Comparison
Compare BYRN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYRN | RLMD |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.6M | 319.7M |
| IPO Year | 2013 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BYRN | RLMD |
|---|---|---|
| Price | $10.78 | $7.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $41.50 | $10.25 |
| AVG Volume (30 Days) | 320.1K | ★ 542.6K |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.21 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $16,566,295.00 | $13,070.00 |
| Revenue This Year | $21.64 | N/A |
| Revenue Next Year | $18.99 | N/A |
| P/E Ratio | $29.98 | ★ N/A |
| Revenue Growth | ★ 1692.08 | 154.83 |
| 52 Week Low | $11.13 | $0.24 |
| 52 Week High | $33.56 | $5.12 |
Technical Indicators
Market Signals| Indicator | BYRN | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 30.49 | 79.95 |
| Support Level | N/A | $3.65 |
| Resistance Level | $13.79 | N/A |
| Average True Range (ATR) | 0.82 | 0.47 |
| MACD | -0.02 | 0.20 |
| Stochastic Oscillator | 13.62 | 98.67 |
Price Performance
Historical ComparisonAbout BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.